Beyond Viral Suppression.
作者信息
Behrens Georg M N
机构信息
Department for Rheumatology and Immunology, Hannover Medical School, Hannover, Germany.
出版信息
Open Forum Infect Dis. 2021 Jan 30;8(10):ofab044. doi: 10.1093/ofid/ofab044. eCollection 2021 Oct.
Abstract
摘要
相似文献
1
Beyond Viral Suppression.超越病毒抑制
Open Forum Infect Dis. 2021 Jan 30;8(10):ofab044. doi: 10.1093/ofid/ofab044. eCollection 2021 Oct.
2
Looking Beyond the Cascade of HIV Care to End the AIDS Epidemic: Estimation of the Time Interval From HIV Infection to Viral Suppression.超越艾滋病病毒治疗流程以终结艾滋病流行：对从感染艾滋病病毒到病毒抑制的时间间隔的估计
J Acquir Immune Defic Syndr. 2016 Nov 1;73(3):348-355. doi: 10.1097/QAI.0000000000001120.
3
Understanding Local Spatial Variation Along the Care Continuum: The Potential Impact of Transportation Vulnerability on HIV Linkage to Care and Viral Suppression in High-Poverty Areas, Atlanta, Georgia.了解照护连续过程中的局部空间差异：交通脆弱性对佐治亚州亚特兰大高贫困地区艾滋病毒治疗衔接和病毒抑制的潜在影响
J Acquir Immune Defic Syndr. 2016 May 1;72(1):65-72. doi: 10.1097/QAI.0000000000000914.
4
Duration of Viral Suppression and Risk of Rebound Viremia with First-Line Antiretroviral Therapy in Rural Uganda.乌干达农村地区一线抗逆转录病毒治疗的病毒抑制持续时间及病毒血症反弹风险
AIDS Behav. 2017 Jun;21(6):1735-1740. doi: 10.1007/s10461-016-1447-1.
5
Surviving HIV beyond prolonged viral suppression.长期病毒抑制后仍存活的HIV感染者。
Neth J Med. 2017 May;75(4):136-137.
6
"I just believe there is a risk" understanding of undetectable equals untransmissible (U = U) among health providers and HIV-negative partners in serodiscordant relationships in Kenya.“我只是认为存在风险”，在肯尼亚的血清不一致关系中，卫生提供者和 HIV 阴性伴侣对无法检测到等于无法传播（U=U）的理解。
J Int AIDS Soc. 2020 Mar;23(3):e25466. doi: 10.1002/jia2.25466.
7
Long-term virological suppression on first-line efavirenz + tenofovir + emtricitabine/lamivudine for HIV-1.一线治疗方案中应用依非韦伦+替诺福韦+恩曲他滨/拉米夫定治疗 HIV-1 可实现长期病毒学抑制。
AIDS. 2019 Mar 15;33(4):745-751. doi: 10.1097/QAD.0000000000002126.
8
Adherence to nonnucleoside reverse transcriptase inhibitor-based HIV therapy and virologic outcomes.坚持基于非核苷类逆转录酶抑制剂的艾滋病治疗及病毒学结果。
Ann Intern Med. 2007 Apr 17;146(8):564-73. doi: 10.7326/0003-4819-146-8-200704170-00007.
9
Retention in Continuous Care and Sustained Viral Suppression.持续护理中的留存率与持续病毒抑制
J Int Assoc Provid AIDS Care. 2017 Jan/Feb;16(1):42-47. doi: 10.1177/2325957416678929. Epub 2016 Nov 16.
10
"Moving Fourth": A Vision Toward Achieving Healthy Living with HIV Beyond Viral Suppression.“迈向第四”：超越病毒抑制，实现艾滋病毒感染者健康生活的愿景。
AIDS Rev. 2019;21(3):135-142. doi: 10.24875/AIDSRev.19000088.
本文引用的文献
1
Efficacy and Safety of Switching to Dolutegravir With Boosted Darunavir in Virologically Suppressed Adults With HIV-1: A Randomized, Open-Label, Multicenter, Phase 3, Noninferiority Trial: The DUALIS Study.在病毒学抑制的成人HIV-1感染者中换用多替拉韦联合增强型达芦那韦的疗效和安全性：一项随机、开放标签、多中心、3期、非劣效性试验：DUALIS研究
Open Forum Infect Dis. 2020 Aug 13;7(9):ofaa356. doi: 10.1093/ofid/ofaa356. eCollection 2020 Sep.
2
The ethics of switch/simplify in antiretroviral trials: non-inferior or just inferior?抗逆转录病毒治疗试验中转换/简化方案的伦理学问题：非劣效还是仅仅是劣效？
PLoS Med. 2012;9(7):e1001240. doi: 10.1371/journal.pmed.1001240. Epub 2012 Jul 17.
Zotero 插件